Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Leerink 2025 Global Biopharma Conference March 10, 2025 3:00 PM ET Company Participants John Leonard - Chief Executive Officer Conference Call Participants Mani Foroohar - Leerink Partners Mani Foroohar Great. And welcome back to the next session of the 2025 Leerink Global Healthcare Conference.
Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 drug for HAE, is the closest to commercialization, expected by 2027, but profitability remains distant. Intellia's financials show a cash runway extended through 2027, but additional funding or partnerships will likely be needed for profitability.
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Edward Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Mani Foroohar - Leerink Partners Maury Raycroft - Jefferies Lisa Walter - RBC Capital Markets Gena Wang - Barclays Joseph Thome - TD Cowen Brian Cheng - JPMorgan Rick Bienkowski - Cantor Fitzgerald William Pickering - Bernstein Jay Olson - Oppenheimer Silvan Tuerkcan - Citizens JMP Yanan Zhu - Wells Fargo Securities Liisa Bayko - Evercore ISI David Lebowitz - Citi Terence Flynn - Morgan Stanley Operator Good morning, and welcome to Intellia Therapeutics' Fourth Quarter and Full-Year 2024 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics (NTLA 8.52%), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was better than the $1.34 per share loss that analysts had expected, and revenue of $12.9 million, significantly outpacing the $7 million estimate.
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $1.46 per share a year ago.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?
Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided.
